A Sensitive LC/MS/MS Method for the Quantitation of Telmisartan in Human Plasma using the Agilent 6460 Triple Quadrupole LC/MS with Jet Stream Technology

Importance of the topic

The ability to accurately quantify pharmaceuticals in biological matrices underpins drug development, therapeutic monitoring, and safety assessment. Telmisartan, a widely used angiotensin II receptor blocker for hypertension management, often requires highly sensitive assays to support low-dose pharmacokinetic studies and bioequivalence trials.

Objectives and study overview

This application note describes the development and validation of a robust LC/MS/MS method for measuring telmisartan in human plasma at concentrations as low as 50 pg/mL. The assay employs an Agilent 1260 Infinity LC system coupled to an Agilent 6460 Triple Quadrupole MS with Jet Stream technology. Performance characteristics are benchmarked against literature methods to demonstrate enhanced sensitivity and reproducibility.

Methodology and instrumentation

Sample preparation relies on a straightforward protein precipitation protocol:

• Spiking: human plasma (180 µL) was fortified with aqueous telmisartan standards (50–5000 pg/mL) and a telmisartan-d3 internal standard (300 pg/mL).
• Extraction: proteins were precipitated with 500 µL cold acetonitrile, vortexed, centrifuged, and supernatant concentrated under vacuum.
• Reconstitution: residues were dissolved in 200 µL of water/methanol (9:1, v/v) before injection.

LC conditions:

• System: Agilent 1260 Infinity LC.
• Column: ZORBAX RRHT Eclipse Plus-C8, 3.0×50 mm, 1.8 µm, 45 °C.
• Mobile phase: 10 mM ammonium acetate (A) and acetonitrile (B); flow rate 0.5 mL/min; gradient from 2 % B to 95 % B in 0.5 min, hold 2 min, return to 20 % B, hold 2.4 min.

MS conditions (positive ESI with Jet Stream):

• Drying gas: 350 °C, 10 L/min; sheath gas: 400 °C, 11 L/min; nebulizer: 40 psi; capillary voltage: 4000 V; fragmentor: 180 V; delta EMV: 300 V.
• MRM transitions: telmisartan 515.2→275.6 (CE 52 V); telmisartan-d3 518.4→279.2 (CE 50 V).

Data integration and quantitation were performed using Agilent MassHunter Quantitative Analysis software.

Main results and discussion

The method exhibited a linear dynamic range of 50 to 5000 pg/mL with correlation coefficients (R²) ≥ 0.9968. The lower limit of quantitation (LLOQ) at 50 pg/mL is an order of magnitude lower than previously reported values (0.5 ng/mL). Precision (%RSD) and accuracy at calibration levels and quality control samples met FDA bioanalytical criteria, with accuracy between 87 and 103 % and precision under 12 % RSD. Carryover was negligible, with no quantifier peak in post-sequence blanks.

Benefits and practical application of the method

• High sensitivity supports low-dose pharmacokinetic and bioequivalence studies.
• Simplified sample preparation reduces hands-on time and increases throughput.
• Robust performance and minimal carryover ensure data quality for clinical trials and therapeutic monitoring.

Future trends and potential applications

Advances in ionization source design and microflow LC are expected to further enhance sensitivity and reduce solvent consumption. The workflow may be extended to multiplexed assays for simultaneous quantification of multiple cardiovascular drugs. Integration with automated sample preparation platforms could streamline clinical bioanalysis.

Conclusion

A highly sensitive and selective LC/MS/MS assay for telmisartan in human plasma was established using Agilent 1260 Infinity LC and 6460 Triple Quadrupole MS with Jet Stream technology. The method achieves an LLOQ of 50 pg/mL, robust linearity, and compliance with regulatory criteria, offering significant advantages for low-dose pharmacokinetic and clinical studies.

References

• Li P., Wang Y., Tang Y., Fawcett J.P., Cui Y., Gu J. Determination of telmisartan in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Chromatography B. 828 (2005) 126–129.
• Yan T., Li H., Deng L., Guo Y., Yu W., Fawcett J.P., Zhang D., Cui Y., Gu J. Liquid chromatographic-tandem mass spectrometric method for the simultaneous quantitation of telmisartan and hydrochlorothiazide in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 48 (2008) 1225–1229.